Pakistan Pharma | About | Products | Services | Contact


Transamin binds strongly with the lysine bonding site (LBS), the site of fibrin affinity of plasmin and plasminogen, and inhibits the bonding of plasmin and plasminogen to fibrin. Therefore, the deg-radation of fibrin by plasmin is strongly inhibited. In the presence of antiplasmins, such as ox2- macro globulin, in the plasma, the antifibrinolytic action of Transamin is even further strengthened.

Hemostatic action
Abnormally exacerbated plasmin causes inhibition of platelet aggregation, decomposition of coagulation factors, etc., but even mild exacerbation causes characteristic fibrin degeneration to occur first. Therefore, in cases of ordinary hemorrhages, Transamin appears to cause hemostasis by suppressing this fibrin degradation.

Antiallergic and anti-inflammatory actions
Transamin inhibits the production of kinin and other active peptides, etc. due to plasmin, which cause increase of vascular permeability, allergies, and inflammatory lesions.

Blood concentrations
The concentrations in the blood, when 250 mg and 500 mg of Transamin were administered orally to healthy adults, reached peak values 3.9 ug/ml (250 mg administration) and 6.0 ug/ml (500mg administration) 2,3 hours after administration. The biological half-lives were 3.1 hours and 3.3 hours, respectively.

When 500 mg of Transamin was administered orally to healthy adults the rate of excretion in the urine was about 30-52% by 24 hours after administration.

Clinical Results
Antihemorrhagic action
In an open clinical trial performed on 2802 patients with hemorrhagic tendencies during leukemia, hypoplastic anemia or purpura thought to involve systemic fibrinolytic exacerbation, or with pulmonary, genital or renal hemorrhages or abnormal hemorrhages during or utter prostate surgery thought to involve local fibrinolytic exacerbation. Transaminshowed hemostatic effects in 73.6% (2063 cases).

Antiallergic and anti-inflammatory actions
Skin disorders
The effects of Transamin against skin disorders, including itching, rubor and swelling was compared to placebo in a double blind study in 67 patients (Transamin 35, placebo 32) with eczema or similar diseases, toxic exanthema and drug rash. The result showed that 22 patients (62.9%) in the Transamingroup and 10 patients (31.3%) in the placebo group had a response more than good, and a significant difference was recognized between ' these groups10) (p<0.05). An open clinical study in 223 patients with skin diseases (eczema or similar diseases, urticaria, drug rash and toxic erythema) showed that this drug was effective against itching, swelling and erythema in 135 patients (60.5%).

Otolaryngological disorders

The effects of Transamin against otolaryngologic disorders, including pain, swelling and robot ware compared to placebo in a double blind study in 168 patients (Transamin84, placebo 84) with acute laryngopharyngitis, acute tonsillitis and stomatitis. The result showed that 44 patients (52.4%) in Transamingroup and 22 patients (26.2%) in placebo group had a response more than good, and a significant difference was recongnized between these group11)(p<0.05). In an open clinical trial performed on 168 patients with tonsillitis, laryngopharyngitis, stomatitis, and gingivitis, the effects against pain, swelling and rubor were observed in 119 patients (70.8%).

Transamin Side Effects | Transamin Dosage | Transamin Indications

Copyrights© Pakistan Pharma. All Rights Reserved